| Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma O Zavidij, NJ Haradhvala, TH Mouhieddine, R Sklavenitis-Pistofidis, S Cai, ... Nature cancer 1 (5), 493-506, 2020 | 264 | 2020 |
| Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression M Bustoros, R Sklavenitis-Pistofidis, J Park, R Redd, B Zhitomirsky, ... Journal of Clinical Oncology 38 (21), 2380, 2020 | 146 | 2020 |
| Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies SP Treon, L Xu, ML Guerrera, C Jimenez, ZR Hunter, X Liu, M Demos, ... Journal of Clinical Oncology 38 (11), 1198, 2020 | 144 | 2020 |
| Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant TH Mouhieddine, AS Sperling, R Redd, J Park, M Leventhal, CJ Gibson, ... Nature communications 11 (1), 2996, 2020 | 118 | 2020 |
| Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression Y Kawano, O Zavidij, J Park, M Moschetta, K Kokubun, TH Mouhieddine, ... The Journal of clinical investigation 128 (6), 2487-2499, 2018 | 97 | 2018 |
| A phase Ib/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma IM Ghobrial, CJ Liu, RA Redd, RP Perez, R Baz, O Zavidij, ... Clinical Cancer Research 26 (2), 344-353, 2020 | 84 | 2020 |
| Progression risk stratification of asymptomatic Waldenström macroglobulinemia M Bustoros, R Sklavenitis-Pistofidis, P Kapoor, CJ Liu, E Kastritis, ... Journal of Clinical Oncology 37 (16), 1403, 2019 | 84 | 2019 |
| Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine AK Dutta, JB Alberge, R Sklavenitis-Pistofidis, ED Lightbody, G Getz, ... Nature Reviews Clinical Oncology 19 (4), 223-236, 2022 | 71 | 2022 |
| Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study H El-Khoury, DJ Lee, JB Alberge, R Redd, CJ Cea-Curry, J Perry, H Barr, ... The Lancet Haematology 9 (5), e340-e349, 2022 | 37 | 2022 |
| Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients R Sklavenitis-Pistofidis, M Capelletti, CJ Liu, M Reidy, O Zavidij, D Huynh, ... Blood, The Journal of the American Society of Hematology 132 (24), 2608-2612, 2018 | 35 | 2018 |
| Progression signature underlies clonal evolution and dissemination of multiple myeloma YJ Shen, Y Mishima, J Shi, R Sklavenitis-Pistofidis, RA Redd, ... Blood, The Journal of the American Society of Hematology 137 (17), 2360-2372, 2021 | 31 | 2021 |
| Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis R Boiarsky, NJ Haradhvala, JB Alberge, R Sklavenitis-Pistofidis, ... Nature Communications 13 (1), 7040, 2022 | 29 | 2022 |
| Single-cell RNA sequencing: one step closer to the clinic R Sklavenitis-Pistofidis, G Getz, I Ghobrial Nature Medicine 27 (3), 375-376, 2021 | 24 | 2021 |
| Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma I Aldoss, M Capelletti, J Park, RS Pistofidis, R Pillai, T Stiller, JF Sanchez, ... Leukemia 33 (1), 266-270, 2019 | 22 | 2019 |
| Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma R Sklavenitis-Pistofidis, MP Aranha, RA Redd, J Baginska, ... Cancer Cell 40 (11), 1358-1373. e8, 2022 | 21 | 2022 |
| Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia JM Bouyssou, CJ Liu, M Bustoros, R Sklavenitis-Pistofidis, Y Aljawai, ... PloS one 13 (10), e0204589, 2018 | 21 | 2018 |
| Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma I Sahin, Y Kawano, R Sklavenitis-Pistofidis, M Moschetta, Y Mishima, ... Blood Advances 3 (7), 995-1002, 2019 | 19 | 2019 |
| Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia Y Konishi, R Sklavenitis-Pistofidis, H Yue, F Ferrari, RA Redd, ... Cancer Cell 40 (1), 6-8, 2022 | 17 | 2022 |
| Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes M Bustoros, S Anand, R Sklavenitis-Pistofidis, R Redd, EM Boyle, ... Nature communications 13 (1), 3449, 2022 | 16 | 2022 |
| Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group M Bustoros, E Kastritis, R Sklavenitis‐Pistofidis, CJ Liu, K Hornburg, ... American Journal of Hematology 94 (5), E146-E149, 2019 | 11 | 2019 |
Irene GhobrialDana-Farber Cancer Institute在 dfci.harvard.edu 的电子邮件经过验证
